AI assistant
Protara Therapeutics, Inc. — Director's Dealing 2019
Jan 3, 2019
34057_dirs_2019-01-03_72803f3f-e73f-4eba-a44d-03464a3ecf10.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PROTEON THERAPEUTICS INC (PRTO)
CIK: 0001359931
Period of Report: 2018-12-31
Reporting Person: Eldridge, George Arthur (Sr VP, CFO, Treasr, Asst Secy)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-12-31 | Common Stock | A | 2448 | $1.93 | Acquired | 29132 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1545 | Indirect |
Footnotes
F1: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan for the plan period of July 1, 2018 through December 31, 2018 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2: These securities were purchased by the reporting person as custodian for three minor children under the Uniform Transfers to Minors Act. The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.